Global Mycoplasma Testing Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024

Industry : Healthcare Date : July 27th, 2018
Tutorials Get 15% Discount on First Report

The global mycoplasma testing market was valued at USD 606.9 million in 2017, and is expected to reach USD 1358.2 million by 2024, at a CAGR of 12.3% during 2018-2024. The growth can be primarily attributed to the increasing incidence of mycoplasma contamination, and increasing research and development activities in the field of life sciences. In addition, increasing capital investment in the field of life sciences coupled with stringent regulatory norms to reduce contamination is also projected to drive the market during the forecast period. The years used for the assessment are as follows;

Historical year: 2014, 2015, and 2016

Base year: 2017

Forecast period: 2018 – 2024

RESEARCH METHODOLOGY

The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;

  • Obtaining historical data of the market based on news, articles, publications, annual reports, white papers, surveys, and other secondary sources
  • Interacting with key opinion leaders of the market and developing data points based on interaction with them
  • Study of past trends in the market and their year on year Impact on the market size and share
  • Analyzing the collected data points
  • Bridging the data points to calculate the total mycoplasma testing market and its various segments
  • Anticipating potential risks
  • Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global mycoplasma testing market
  • Finalizing the overall size and share of the global mycoplasma testing market

OBJECTIVES:

  • To analyze market trends, opportunities, drivers, and restraints associated with the global mycoplasma testing market
  • To study market response with respect to the mergers and acquisitions in the industry
  • To profile key companies operating in the mycoplasma testing market and provide their competitive landscape

MARKET SCOPE

The research scope for mycoplasma testing market is as follows:

By Product Type

  • Instruments
  • Kits & Reagents
    • Elimination Kits & Reagent
    • Standards & Controls
    • PCR Assay
    • Stains
    • Nucleic Acid Detection
    • Other
  • Services

By Technology

  • ELISA (Enzyme-linked Immunosorbent Assay)
  • Microbial Culture Techniques
  • PCR (Polymerase Chain Reaction)
  • Indirect Assay
  • Enzymatic Methods
  • Direct Assay

By Application

  • Virus Testing
  • Cell Line Testing
  • End of Production Cells Testing
  • Other

By End-user

  • Academic Research Institutions and Organizations
  • Pharmaceutical & Biotechnology Companies
  • Cell Banks
  • Contract Service Laboratories
  • Government Agencies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

The demand for mycoplasma testing in biopharmaceutical sector is on the rise as mycoplasma contaminates the cell culture and affects the entire production batch. The bacteria grow in cell culture media and can reach very high numbers without causing visible changes in the culture while affecting cell cultures (changes in metabolism, biochemical or immunologic properties, growth, and viability). The mycoplasma testing offers revolutionary opportunities for pharmaceutical and biotechnology companies. To minimize the financial risk and maintain product quality, manufactures collect thousands of samples for sterility and bioburden testing every year. With Increasing research and development activities and growing demand for biopharmaceutical products, regulatory bodies such as FDA and EMA are expected to increasingly approve mycoplasma testing for biopharmaceutical products in coming years.

The factors which are driving the growth of the market are the increasing incidence of mycoplasma contamination, and increasing research and development activities in the field of life sciences. In addition, increasing capital investment in the field of life sciences coupled with stringent regulatory norms to reduce contamination is also projected to drive the market during the forecast period.

Geographically, North America held the largest share of the market in 2017. The growth in the region is attributed to the increasing research and development activities in the biopharmaceutical industries and availability of the various types of kit and reagents. Moreover, continued research and development on new assays and kits, and growing demand from end-user industries such as pharmaceutical & biotechnology, cell banks, and contract service laboratories is further boosting the market growth in the region. Europe held the second largest share of the global mycoplasma testing market in 2017. Asia-Pacific is expected to grow at the highest CAGR during 2018-2024. The growth of mycoplasma testing market in Asia-Pacific region is attributed to growing pharmaceutical and biotechnological industry and strong demand for mycoplasma testing from these sectors. Moreover, technological advancements in mycoplasma testing methods and increasing investment in R&D activities are further propelling the market growth in the region.

Some of the key companies operating in the market include Roche Diagnostics, Lonza Group Ltd, Merck KGaA, PromoCell GmbH, InvivoGen, Charles River Laboratories, Inc., SGS SA, American Type Culture Collection, Bionique Testing Laboratories, Inc., Biological Industries Israel Beit Haemek Ltd, and among others.

Global Mycoplasma testing market

TABLE OF CONTENTS

CHAPTER 1. Market Scope and Methodology

1.1. Research methodology

1.2. Research scope & assumptions

1.3. List of data sources

CHAPTER 2. Executive Summary

2.1. Global Mycoplasma Testing – Market Snapshot

CHAPTER 3. Industry Analysis

3.1. Market definition

3.2. Market segmentation

3.3. Key findings of the global mycoplasma testing market

3.4. Value chain analysis

3.5. Regulatory overview

3.6. Market opportunities & trends

3.7. Market dynamics

3.7.1. Market driver analysis

  3.7.1.1. Increasing government initiatives and rise in funding from the governmental bodies

  3.7.1.2. Stringent regulatory norms to reduce contamination

  3.7.1.3. Increasing incidence of mycoplasma infection

  3.7.1.4. Increasing research and development activities in the field of life sciences

3.7.2. Market restraint analysis

           3.7.2.1. High cost of testing equipment

3.7.3. Industry Analysis-Porters five forces of analysis

CHAPTER 4. Competitive Outlook

4.1. Competitive analysis

4.2. Competitive factors

4.3. Strategies adopted

CHAPTER 5. Global Mycoplasma Testing Market Size and Forecast (2014 – 2024)

5.1. Global Mycoplasma Testing Market, By Product Type (USD Million)

5.1.1. Instruments

5.1.2. Kits & Reagents

   5.1.2.1. Elimination Kits & Reagent

   5.1.2.2. Standards & Controls

   5.1.2.3. PCR Assay

   5.1.2.4. Stains

   5.1.2.5. Nucleic Acid Detection

   5.1.2.6. Other

5.1.3. Services

5.2. Global Mycoplasma Testing Market, By Technology (USD Million)

5.2.1. ELISA (Enzyme-linked Immunosorbent Assay)

5.2.2. Microbial Culture Techniques

5.2.3. PCR (Polymerase Chain Reaction)

5.2.4. Indirect Assay

5.2.5. Enzymatic Methods

5.2.6. Direct Assay

5.3. Global Mycoplasma Testing Market, By Application (USD Million)

5.3.1. Virus Testing

5.3.2. Cell Line Testing

5.3.3. End of Production Cells Testing

5.3.4. Other

5.4. Global Mycoplasma Testing Market, By End-user (USD Million)

5.4.1. Academic Research Institutions and Organizations

5.4.2. Pharmaceutical & Biotechnology Companies

5.4.3. Cell Banks

5.4.4. Contract Service Laboratories

5.4.5. Government Agencies

CHAPTER 6. Global Mycoplasma Testing Market Size and Forecast, By Geography (2014-2024)

6.1. North America Mycoplasma Testing Market

6.1.1. North America Mycoplasma Testing Market, By Product Type (USD Million)

6.1.2. North America Mycoplasma Testing Market, By Technology (USD Million)

6.1.3. North America Mycoplasma Testing Market, By Application (USD Million)

6.1.4. North America Mycoplasma Testing Market, By End-user (USD Million)

6.1.5. North America Mycoplasma Testing Market, By Country (USD Million)

  6.1.5.1. US

  6.1.5.2. Canada

  6.1.5.3. Mexico

6.2. Europe Mycoplasma Testing Market

6.2.1. Europe Mycoplasma Testing Market, By Product Type (USD Million)

6.2.2. Europe Mycoplasma Testing Market, By Technology (USD Million)

6.2.3. Europe Mycoplasma Testing Market, By Application (USD Million)

6.2.4. Europe Mycoplasma Testing Market, By End-user (USD Million)

6.2.5. Europe Tube Market, By Country (USD Million)

   6.2.5.1. Germany

  6.2.5.2. Italy

  6.2.5.3. France

  6.2.5.4. U.K.

  6.2.5.5. Rest of Europe

6.3. Asia-Pacific Mycoplasma Testing Market

6.3.1. Asia-Pacific Mycoplasma Testing Market, By Product Type (USD Million)

6.3.2. Asia-Pacific Mycoplasma Testing Market, By Technology (USD Million)

6.3.3. Asia-Pacific Mycoplasma Testing Market, By Application (USD Million)

6.3.4. Asia-Pacific Mycoplasma Testing Market, By End-user (USD Million)

6.3.5. Asia-Pacific Mycoplasma Testing Market, By Country (USD Million)

  6.3.5.1. China

  6.3.5.2. India

  6.3.5.3. Japan

  6.3.5.4. Australia

  6.3.5.5. Rest of Asia-Pacific

6.4. Rest of the World (RoW) Mycoplasma Testing Market

6.4.1. Rest of the World Mycoplasma Testing Market, By Product Type (USD Million)

6.4.2. Rest of the World Mycoplasma Testing Market, By Technology (USD Million)

6.4.3. Rest of the World Mycoplasma Testing Market, By Application (USD Million)

6.4.4. Rest of the World Mycoplasma Testing Market, By End-user (USD Million)

6.4.5. ROW Mycoplasma Testing Market, By Region (USD Million)

   6.4.5.1. Central and South America

   6.4.5.2. Middle East and Africa (MEA)

CHAPTER 7. Key Players and Strategic Developments

7.1. Roche Diagnostics

7.1.1. Business Overview

7.1.2. Product and Service Offering

7.1.3. Financial Overview

7.1.4. Strategic Developments

7.2. Lonza Group Ltd

7.2.1. Business Overview

7.2.2. Product and Service Offering

7.2.3. Financial Overview

7.2.4. Strategic Developments

7.3. Merck KGaA

7.3.1. Business Overview

7.3.2. Product and Service Offering

7.3.3. Financial Overview

7.3.4. Strategic Developments

7.4. PromoCell GmbH

7.4.1. Business Overview

7.4.2. Product and Service Offering

7.4.3. Financial Overview

7.4.4. Strategic Developments

7.5. InvivoGen.

7.5.1. Business Overview

7.5.2. Product and Service Offering

7.5.3. Financial Overview

7.5.4. Strategic Developments

7.6. Charles River Laboratories, Inc.

7.6.1. Business Overview

7.6.2. Product and Service Offering

7.6.3. Financial Overview

7.6.4. Strategic Developments

7.7. SGS SA

7.7.1. Business Overview

7.7.2. Product and Service Offering

7.7.3. Financial Overview

7.7.4. Strategic Developments

7.8. American Type Culture Collection

7.8.1. Business Overview

7.8.2. Product and Service Offering

7.8.3. Financial Overview

7.8.4. Strategic Developments

7.9. Bionique Testing Laboratories, Inc.

7.9.1. Business Overview

7.9.2. Product and Service Offering

7.9.3. Financial Overview

7.9.4. Strategic Developments

7.10. Biological Industries Israel Beit Haemek Ltd

7.10.1. Business Overview

7.10.2. Product and Service Offering

7.10.3. Financial Overview

7.10.4. Strategic Developments

Global Mycoplasma Testing Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation and Forecast 2024